Skip to content
Search

Latest Stories

Dementia: Pharmacists to explore how to enhance patient care in upcoming webinar

Dementia: Pharmacists to explore how to enhance patient care in upcoming webinar

Experts will address the growing challenges in dementia treatment and explore ways to optimise pathways between primary and secondary care

Dementia and Alzheimer's disease remained the leading cause of death in England and Wales in 2023, maintaining the pre-pandemic trend, according to the latest data from the Office for National Statistics (ONS).

The figures reveal that there were 66,876 deaths with an underlying cause of dementia and Alzheimer's disease, accounting for 11.6% of all deaths registered that year.


In response to this growing health concern, Luye Pharma is hosting a free special educational webinar on 6 November 2024 (timing: 18:30 - 20:00) for healthcare professionals.

Titled "Treating Dementia in 2024: Optimising Pathways Between Primary and Secondary Care," the online session will focus on addressing the ever-increasing challenges in dementia treatment and how to optimise pathways between primary and secondary care.

The webinar will feature expert speakers from the field of dementia care, including Dr. Jill Rasmussen, Primary Care Specialist in dementia, mental health, and intellectual disabilities; Delia Bashara, Consultant Pharmacist for the Mental Health of Older Adults and Dementia at South London and Maudsley NHS Foundation Trust; and Khaleel Loonat, Senior Clinical Pharmacist and Advanced Clinical Practitioner.

Dr. Rasmussen will cover "Issues and Challenges in Managing People with Dementia: Focus on Pathways and Treatments," Delia Bashara will speak on "Dementia Pathways in Secondary Care," and Khaleel Loonat will discuss "Dementia Care: The Use of Transdermal Patches in Primary Care."

The session aims to provide valuable guidance on managing dementia within the current healthcare environment.

Luye Pharma, specializing in diseases of the central nervous system (CNS), has developed Zeyzelf, a twice-weekly transdermal rivastigmine patch for treating Alzheimer’s dementia.

This webinar presents an opportunity for healthcare professionals to learn more about managing and treating dementia.

You can register for the event at the following link: https://hcpconnect-uniphar.com/treating-dementia-in-2024/

Nearly 1 million people in the UK are estimated to have dementia. In hospitals, one in four beds is occupied by individuals over the age of 65 who are living with dementia. Projections suggest that by 2040, up to 1.7 million people could be living with the condition in England and Wales.

 

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less